It was toward the end of a half-hour interview with Flemming Ornskov, head of the state’s fastest-growing drug company, that I asked his about the array of glass trophies that filled two shelves on the wall behind his desk.
The trophies mostly commemorated the many acquisitions Shire (Nasdaq: SHPG) had made in recent years that have fueled that growth. That was, in fact, the reason I asked for the interview with Ornskov: To get the story behind the company that bounced back with a vengeance from its breakup two years ago from a planned $54 billion merger with AbbVie to become the world’s fastest-growing pharmaceutical company.
